3 Drugs Stocks Nudging The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 16 points (-0.1%) at 18,296 as of Wednesday, May 20, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,497 issues advancing vs. 1,463 declining with 190 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Sarepta Therapeutics ( SRPT), up 56.5%, ISIS Pharmaceuticals ( ISIS), up 3.1%, Endo International ( ENDP), up 3.0%, Opko Health ( OPK), up 3.0% and United Therapeutics ( UTHR), up 2.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $6.19 (1.2%) to $510.34 on average volume. Thus far, 445,987 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 835,700 shares. The stock has ranged in price between $503.42-$514.50 after having opened the day at $507.50 as compared to the previous trading day's close of $504.15.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $50.3 billion and is part of the health care sector. Shares are up 22.9% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Regeneron Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.83 (1.2%) to $69.10 on average volume. Thus far, 4.1 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 6.3 million shares. The stock has ranged in price between $68.29-$69.86 after having opened the day at $68.41 as compared to the previous trading day's close of $68.27.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $113.4 billion and is part of the health care sector. Shares are up 15.7% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Bristol-Myers Squibb Company Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Biogen ( BIIB) is up $3.07 (0.8%) to $398.24 on light volume. Thus far, 675,783 shares of Biogen exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $391.61-$399.68 after having opened the day at $394.50 as compared to the previous trading day's close of $395.17.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $93.0 billion and is part of the health care sector. Shares are up 16.5% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts who rate Biogen a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash